JG
KROS icon

Jefferies Group’s Keros Therapeutics KROS Stock Holding History

Jefferies Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.1M Buy
29,319
+16,819
+135% +$583K 0.01% 797
2022
Q2 		$345K Buy
+12,500
New +$548K ﹤0.01% 1121
2021
Q4 		– Sell
-10,000
Closed -$396K – 1837
2021
Q3 		$396K Buy
+10,000
New +$356K ﹤0.01% 1301

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Group's KROS Position: Q3 2022 in Review

Jefferies Group increased its Keros Therapeutics (KROS) stake by 135% in Q3 2022, buying an estimated $583K and bringing the position to 29,319 shares worth $1.1M. The position accounts for 0.01% of the portfolio, ranked #797.

Jefferies Group first reported a position in KROS in Q3 2021 and has held it in 3 quarters since. 113 funds tracked by Wall St. Rank hold KROS as of Q3 2022.

  • Jefferies Group held 29,319 shares of Keros Therapeutics worth $1.1M as of Q3 2022.
  • Jefferies Group bought 16,819 Keros Therapeutics shares in Q3 2022, an estimated $583K.
  • Keros Therapeutics made up 0.01% of Jefferies Group's portfolio in Q3 2022, its #797 holding.
  • Jefferies Group first reported a position in Keros Therapeutics in Q3 2021 and has held it in 3 quarters since.
  • 113 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.